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Abstract
Background: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis which impacts significantly on the quality of
life and work capacity of affected individuals. Recent evidence has shown that early control of inflammation in PsA
leads to improved long-term outcomes. It is postulated that prompt intervention after diagnosis using a remission-
induction treatment strategy will lead to improved outcomes and optimal disease control of PsA.
The aim of the present study was to compare the clinical efficacy of a treatment strategy in newly diagnosed, treatment
naïve PsA subjects, using the combination of golimumab (GOL), methotrexate (MTX) and steroids versus standard care
(MTX monotherapy plus steroids).
Methods/design: GOLMePsA is an investigator initiated, phase IIIb, single-centre, randomised, double-blind, placebo-
controlled, two-armed, parallel-group, imaging-supplemented study. Eighty-eight PsA patients, diagnosed within
24 months prior to screening and treatment naïve, will be randomised at baseline to receive: (arm 1) the combination
of intramuscular/intra-articular prednisolone, MTX and GOL or (arm 2) the combination of intramuscular/intra-articular
prednisolone, MTX and placebo for 24 weeks (interventional period). Primary outcome measure is clinical improvement
(at least 1 unit difference) in the Psoriatic ArthritiS Disease Activity Score (PASDAS) composite index.
Reflecting a “step down” therapeutic approach, all participants successfully completing the interventional period
will be followed up for a further 28 weeks. During this observational period, stable maintenance MTX monotherapy
will continue for both arms, unless in case of intolerance or PsA relapse. In the latter case, additional treatment will be
provided. Overall, the GOLMePsA study length is planned to be 52 weeks.
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Discussion: The hypothesis underlining this study is that very early treatment with first-line GOL reduces disease activity
in PsA, in comparison to conventional therapy.
Trial registration: EudraCT 2013–004122-28. 24/09/2013.
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Background
Psoriatic arthritis (PsA) is a polygenic, chronic inflamma-
tory arthritis affecting up to 0.19% of the general popula-
tion [1] and 3.2% [2] to 34% [3] of individuals with skin
psoriasis. The course of PsA is heterogeneous and variable:
some patients have mild disease whilst others evolve into a
severe arthropathy that is often refractory to conventional
treatments. These cases are frequently associated with
functional disability and accelerated morbidity [4, 5]. A
main hindrance in the treatment of PsA has been the delay
to presentation to rheumatology clinics, of up to 9 years
from symptoms onset. By that time the majority of affected
individuals (67%) has an established, erosive arthropathy
with a substantial degree of functional impairment [6–8].
However, up to 27% of PsA cases show radiographic da-
mage within 2 years of symptom onset [9, 10]. Even a short
delay of 6 months to presentation may lead to permanent
work instability [11].
Over the past two decades, mounting evidence from
rheumatoid arthritis (RA) studies has shown that early,
aggressive treatment using synthetic and biologic
disease-modifying anti-rheumatic drugs (sDMARDs and
bDMARDs, respectively) improves the outcome of the
disease concerning articular damage and disability [12].
Such a novel therapeutic approach allowed clinical remis-
sion to become an achievable goal in many patients
treated with bDMARDs, chiefly Tumor Necrosis Factor α
(TNFα) inhibitors (TNFi) [13, 14]. As a result, the con-
cepts of “window of opportunity” and “treat-to-target”
have become popular in RA treatment. By contrast, data
in PsA are still sparse [15], with only limited evidence on
the efficacy of sDMARDs such as methotrexate (MTX)
[16] or leflunomide [17]. To date, only TNFi have shown
efficacy on all clinical manifestations of PsA [18–21] as
well as on delaying structural damage [22]. The safety
and efficacy of golimumab (GOL) used for reducing
signs and symptoms of active PsA and the associated
skin and nail disease was evaluated in the GO-REVEAL
trial) [19] with benefits maintained in the long term
[23]. Further, in the same trial GOL was associated with
inhibition of structural damage (weeks 24 and 52), per-
sistent articular and cutaneous improvements at week
104 and significant improvements in the Patients’
Reported Outcomes (PROs). Currently, GOL, alone or
associated with MTX, is indicated to treat active and
progressive PsA in adults irresponsive or intolerant to
previous sDMARD therapy.
Structural abnormalities are insidious in the early
disease stages of PsA, rendering radiography a measurable
outcome lacking of sensitivity in these patients. Whole
body MRI (WB-MRI) allows axial and peripheral multi-
joint assessments in one single investigation and is a
feasible tool for detection of subclinical inflammation in
patients with PsA, particularly for enthesitis and bone
marrow oedema (BMO) [24]. Evidence from RA suggests
that subclinical BMO is one of the main predictors for on-
going radiographic progression, even in the presence of
clinical remission [25]. In SpA, there is evidence that
BMO may be a predictor of future radiographic axial
damage [26]. The ability of WB-MRI and US [27, 28] to
identify subclinical inflammation is particularly useful
for the quantification of the total inflammatory burden
in PsA [29] and in understanding the features of disease
remission after a course of therapy.
To date, there are no data on the role of WB-MRI as an
outcome measure in PsA. Further, the use of bDMARDs
on treatment naïve, early diagnosed PsA patients has not
been addressed in double blind randomized clinical trials.
It is therefore postulated that the GOLMePsA study will
show that an early aggressive intervention in PsA imme-
diately after diagnosis, using GOL combined with dose
escalating MTX protocol and intra-articular or intramus-
cular corticosteroid, could ameliorate significantly the dis-
ease activity and even lead to a state of minimal disease
activity (MDA) [30], or near clinical remission, along with
complete ablation of inflammation as shown by WB-MRI
at 24 weeks.
Study aims
The aim of this study is to assess in early diagnosed
treatment naïve PsA, the clinical efficacy of a treatment
strategy comprising of the combination of GOL plus
MTX plus steroids versus standard care (MTX mono-
therapy plus steroids) using clinical and imaging out-
come measures at 24 weeks.
Methods
Research hypothesis
The GOLMePsA trial was designed to address two
different hypotheses:
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 First, that early intervention in recently diagnosed
and treatment-näive PsA, through the combination
of GOL and MTX plus corticosteroids will lead to
clinical improvement reflected by at least 1 unit
difference on the scale measured by the Psoriatic
ArthritiS Disease Activity Score (PASDAS) [31–34]
at week 24. The improvement will be superior to
that shown by the combination of MTX plus
placebo plus corticosteroids (conventional therapy).
 Secondly, that a subset of PsA patients at
presentation have a substantial amount of
subclinical articular and/or entheseal inflammation
and this can be detected by WB-MRI and US.
Using these imaging techniques will allow the
identification of subjects whose response to therapy
has been successful even at the subclinical level.
Primary objective
The primary objective of this study is to assess whether
the combination of GOL with MTX and steroids is supe-
rior to standard care (MTX monotherapy plus steroids) in
patients with early treatment naïve PsA using the PAS-
DAS score at 24 weeks as the primary outcome measure.
Secondary objective(s)
 To assess the extent of association between clinical
and imaging joint assessments at baseline.
 To assess the extent of association between clinical
and imaging responses to therapy.
 To assess whether responses on imaging outcomes
are associated with steroid therapy.
 To assess the superiority of combination therapy
over standard treatment in improving patient-
reported QoL and health status.
 To identify baseline variables which may be
modifiers of clinical or imaging response (e.g.:
symptom duration, immunological parameters).
Trial design
GOLMePsA is an investigator initiated, phase IIIb, single-
centre, randomised, double-blind, placebo-controlled, two-
armed, parallel-group, imaging-supplemented study.
A total of 88 patients with PsA, diagnosed within
24 months prior to screening and treatment näive, will
be randomised to compare:
 The combination of intramuscular/intra-articular
prednisolone and MTX plus GOL
TO
 The combination of intramuscular/intra-articular
prednisolone and MTX plus placebo
The above described interventional period will last
24 weeks. All participants successfully completing this
phase will be followed up for other 28 weeks (observa-
tional period). Overall, the GOLMePsA study length is
planned to be 52 weeks (see Figs. 1 and 2).
Eligibility
The target population is early diagnosed (within 2 years
from screening date), treatment naïve PsA cases who
satisfy the ClASsification criteria for Psoriatic ARthritis
(CASPAR) [35]. A full list of inclusion and exclusion cri-
teria for eligibility and subsequent randomization into
this study are detailed in Table 1.
Recruitment
This study is being conducted at the Chapel Allerton
Hospital (CAH) Outpatient Department and Research
Facility, part of the Leeds Teaching Hospitals National
Health Service (NHS) Trust in Leeds, United Kingdom.
Potential study candidates may also be identified via
rheumatology clinics at Participant Identification Centres
(PICs) within the Yorkshire Region (see also acknowled-
gements section). Potential candidates are provided with
verbal and written details about the trial (Participant
Information Sheet and Informed Consent Document) be-
fore being contacted by the main research team based at
CAH. Potential candidates have as long as they need to
consider participation. Assenting subjects are invited to
provide informed, written consent before being registered
into the trial and formally assessed for eligibility.
Consent to the GOLMePsA trial biological sub-study
Eligible subjects are also invited to take part in a Biological
Sub-study which collects biological samples (blood and
urine) at predefined endpoints. Assenting subjects are
asked to sign an additional, specific consent form.
Screening and registration
Following written informed consent and prior to any
trial-related procedures, participants are registered in
the study enrolment log. All subjects undergo a screening
assessment (Figs. 2 and 3) to determine eligibility for the
study within 4 weeks prior to the baseline assessments.
The research team keeps a “pre-screening” log with de-
tails of all subjects who have been considered for the trial,
regardless of final ineligibility or declined participation.
These subjects are all referred back to outpatient rheuma-
tology clinics in order to receive standard NHS care.
Randomisation
Following registration, confirmation of eligibility, imaging
investigations and completion of baseline assessments and
questionnaires, participants are randomised in a 1:1 ratio
into one of the two treatment arms. Randomization
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assignment is performed with a computer-based pro-
gram which utilizes randomly-permuted block sizes.
Randomisation is stratified by the number of clini-
cally involved joints (oligoarticular: ≤4 joints/polyarti-
cular: >4 joints).
Trial interventions
Treatment is administered in the two study arms as de-
tailed in Table 2. The planned use of corticosteroids,
given as a “bolus” at baseline to all participating subjects,
aims to achieve rapid ablation of inflammation. Partici-
pants in both arms not achieving at least 30% improve-
ment in the Psoriatic Arthritis Response Criteria
(PsARC) [36, 37] at weeks 8 and 12 will receive add-
itional corticosteroid injections. The steroid amount
given between both visits will not exceed a maximum of
120 mg methylprednisolone per patient (or comparable
amount intra-articularly; unless contraindicated or not
tolerated). No further steroids will be allowed between
week 12 and week 24. All participants, in both arms, not
achieving at least 30% of PsARC improvement beyond
week 12 and before week 24 may discontinue the study
medication regimen and be treated as clinically indi-
cated. In this case, they may be withdrawn from the
treatment part of the study.
All subjects completing the interventional period
will continue their MTX and folic acid supplementa-
tion unchanged through the observational period if
tolerated. During the observational period, in case of
increase in disease activity (PsA flare) compared to the
previous assessments, the treating physicians will be
allowed to consider other available NHS therapeutic
options for PsA, such as corticosteroids, sDMARDs or
bDMARDs.
After the end of the interventional period and before
the end of the trial, intramuscular or intra-articular
steroids are not permitted if a clinical or imaging assess-
ment is scheduled within the following 6 weeks.
Fig. 1 Schematic diagram of screening, randomisation and treatment procedures of the GOLMePsA trial. PsARC = Psoriatic arthritis response
criteria; DMARD = Disease modifying anti-rheumatic drug; NICE = National Institute for Health and Care Excellence; PsA = Psoriatic arthritis;
MTX = Methotrexate; CASPAR = ClASsification criteria for Psoriatic Arthritis [39]; WB-MRI = Whole-body magnetic resonance imaging; PASDAS = Psoriatic
arthritis disease activity score; GOL = Golimumab
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Fig. 2 GOLMePsA trial flow diagram. DMARD = Disease-Modifying Anti-Rheumatic Drug; ECG = Electrocardiogram; wbMRI = Whole body magnetic
resonance imaging; US = Ultrasound; QoL = Quality of life; VAS = Visual Analogue Scale; IM = Intra-muscular; SC = Subcutaneous; PsARC = Psoriatic
arthritis response criteria
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Table 1 Eligibility criteria for randomization into the GOLMePsA
trial
Inclusion criteria
1 Male and female subjects aged ≥18 years at the time of signing the
Informed Consent Form.
2 Patients with a diagnosis of PsA and fulfilling CASPAR classification
criteria confirmed within 24 months prior to the screening visit.
3 Patients with active PsA, defined by:
• the presence of at least 3/68 tender joints AND at least 3/66
swollen joints;
OR
• 2 swollen AND 2 tender joints, along with one affected
entheseal site (Achilles tendon and/or plantar fascia).
4 Subjects capable of understanding and signing an Informed Consent
Form prior to any trial-related procedure.
5 Women of childbearing potential (WCBP) or men capable of fathering
children must be using adequate birth control measures (e. g.:
abstinence, oral contraceptives, intrauterine device, barrier method with
spermicide, surgical sterilization) during the study and for 6 months after
receiving the last administration of study drugs. WCBP have to test
negative for pregnancy. Female subjects must agree to not donate eggs
(ova, oocytes) during the study and for 6 months after last dose of study
agent. Male subjects must agree to not donate sperm while in the study
and for 6 months after last dose of study agent.
6 Patients with active current or latent tuberculosis (TB), including
those diagnosed as a result of GOLMePsA trial screening procedures,
who can provide adequate documentation of previous or were
recently commenced on adequate anti-TB treatment according to
local practice guidelines prior to the start of protocol treatment.
Exclusion criteria
General
7 Planned surgery within the study period which is expected to
require omission of any study medication of 28 days or more
Study specific
8 Patient who have received previous treatment with any sDMARD.
9 Patient who have received previous treatment with golimumab or
other TNFi or other biologic or investigational drugs.
10 Any chronic inflammatory arthritis diagnosed before 16 years of age.
11 Patients with current crystal or septic arthritis.
12 The candidates ineligible to (see Table 4) or unsuccessful in bearing
the WB-MRI procedures will not be excluded from the study.
Excluded or concomitant therapy
13 Patient who have received any corticosteroids within 4 weeks prior
to screening.
Exclusions for general safety
14 Patients with significant concurrent medical conditions including:
• Uncompensated congestive heart failure;
• Myocardial infarction within 52 weeks from screening;
• Unstable angina pectoris;
• Uncontrolled arterial hypertension (blood pressure > 160/95
mmHg);
• Severe pulmonary disease;
• History of human immunodeficiency virus infection or
immunodeficiency syndromes;
• Central nervous system demyelinating events suggestive of
multiple sclerosis;
• Renal or gastrointestinal conditions;
Which in the opinion of the investigator place the patient at an
unacceptable risk for participation in the study or would make
implementation of the protocol difficult.
Table 1 Eligibility criteria for randomization into the GOLMePsA
trial (Continued)
15 Patients with cancer or a history of cancer (other than resected
cutaneous basal cell carcinoma and in situ uterine cervical cancer)
within 5 years of screening.
16 Patients with chronic infections of the upper respiratory tract (e. g.:
Sinusitis), chest (e. g.: Bronchiectatic lung disease), urinary tract or
skin (e. g.: Paronychia, chronic ulcers, open wounds) within 4 weeks
of screening.
17 Patients who have a chest radiograph within 3 months prior to the
first administration of study agent that shows an abnormality
suggestive of a malignancy or current active infection, including TB
(for TB exceptions refer also to inclusion criteria 6), histoplasmosis or
coccidioidomycosis.
18 Patients with any ongoing or active infection or any major episode
of infection requiring hospitalization or treatment with IV antibiotics
within the preceding 30 days of screening and/or orally
administered antibiotics in the preceding 15 days of screening.
19 Patients with abnormal liver function including known liver cirrhosis,
fibrosis, or known non-alcoholic steato-hepatitis at the time of
screening or abnormal blood tests as shown by:
• Aspartate aminotransferase / alanine aminotransferase >3×
upper
limit of normality,
OR
• Bilirubin >51 μmol/L.
20 Patients with known severe hypoproteinaemia at the time of screening,
e. g. in nephrotic syndrome or impaired renal function, as shown by:
• Serum Creatinine >133 μmol/L.
21 Patients with known significantly impaired bone marrow function,
e. g. significant anaemia, leukopaenia, neutropaenia or
thrombocytopaenia, as shown by the following laboratory values
at the time of screening:
• White blood cells <3000 × 10^6/L;
• Platelets <125 × 10^9/L;
• Haemoglobin <90 g/L for males and <85 g/L for females.
22 Patients with a history of untreated latent or active TB prior to
screening will not be eligible (for exceptions refer to inclusion criteria 6).
23 Subjects must undergo screening for hepatitis B virus (HBV). At a
minimum, this includes testing for HBsAg (surface antigen), anti-HBs
(surface antibody), and anti-HBc total (core antibody total).
• Subjects who test positive for surface antigen (HBsAg+) are not
eligible for this study, regardless of the results of other hepatitis
B tests.
• Subjects who test negative for surface antigen (HBsAg-) and test
positive for core antibody (anti-HBc+) and surface antibody
(anti-HBs+) are eligible for this study.
• Subjects who test positive only for surface antibody (anti-HBs+)
are eligible for this study.
• Subjects who test positive only for core antibody (anti-HBc+)
must undergo further testing for HBV deoxyribonucleic acid
(HBV DNA test). If the HBV DNA test is positive, the subject
is not eligible for this study. If the HBV DNA test is negative,
the subject is eligible for this study. In the event the DNA test
cannot be performed, the subject is not eligible for the study.
24 Primary or secondary immunodeficiency (history of or currently
active) unless related to primary disease under investigation.
25 Pregnancy, lactation (nursing) or WCBP unwilling to use an effective
birth control measure (detailed in the inclusion criteria 5) whilst
receiving treatment and after the last dose of protocol treatment
as indicated in the relevant Summary of Product Characteristics
(SmPC)/Investigator Brochure (IB).
26 Men unwilling, or whose partners are WCBP who are unwilling to
use an effective birth control measure (detailed in the inclusion
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Assessments, samples and data collection
All protocol-related assessments are recorded on paper
source data sheets (SDS) and stored at the research site.
These data are then entered onto an electronic case re-
port form (eCRF) specific for the GOLMePsA trial. The
trial visits are structured as detailed in Fig. 3.
Biological samples from participants consenting to the
GOLMePsA trial Biological Substudy are collected at
baseline prior to commencement of trial treatment
followed by weeks 12, 24, 36 and 52. In addition, bio-
logical samples are collected at the time of early discon-
tinuation (withdrawal visit) if this falls outside the pre-
specified time-points (see Fig. 3). Personal details are re-
moved from all biological samples collected as part of
the Biological Substudy, after separation into their com-
ponent parts and before testing. For storage and testing
purposes, a pseudo-anonymization unique code will be
generated to link the clinical, imaging and laboratory da-
tabases. All the biological samples are stored in the cen-
tral GOLMePsA Trial Biobank in a laboratory at our
institution. These samples will be used for a range of
studies of direct relevance to the treatment of PsA.
Outcome measures
Clinical efficacy
The primary outcome in this study is the change in
PASDAS score at 24 weeks. The PASDAS is a weighted
composite index encompassing joints counts, an assess-
ment of enthesitis and dactylitis, acute phase reactant,
QoL, and patients’ and physician’s global assessment by
visual analogue scale (VAS). The PASDAS has been
shown to perform well in both oligoarticular and
polyarticular forms of PsA [36] and cut-offs for disease
activity and response have now been developed and vali-
dated using interventional trial data [34].
Secondary outcomes at weeks 12, 24, 36 and 52 in-
clude the Leeds enthesitis index (LEI) [38], the Leeds
dactylitis index basic (LDI-B) [39, 40], the Psoriasis Area
and Severity Index (PASI) score [41], the Body Surface
Area (BSA) affected by psoriasis, the modified Nail Psor-
iasis Severity Index (mNAPSI) [42], the proportion of
subjects achieving MDA, the proportion of subjects
achieving the American College of Rheumatology Re-
sponse Criteria [43], the proportion of subjects achieving
the PASI75 response (defined as having an improvement
of at least 75% in the PASI score compared to baseline
levels). The proportion of subjects achieving PsARC re-
sponse is a secondary outcome to be collected at weeks
8, 12, 24, 36 and 52. The Composite Psoriatic Disease
Activity Index (CPDAI) [44] is a secondary outcome to
be collected at weeks 24 and 52. The proportion of pa-
tients requiring additional steroid therapy, as well as the
cumulative steroid dose up to week 12 of this trial, will
be also recorded as a secondary outcome.
Imaging measures of disease activity
Systematic WB-MRI scanning of the axial and peripheral
skeleton (Table 3) is performed in all suitable subjects
(Table 4), using commercially available Siemens MAG-
NETOM® Verio 3 T scanner with the following se-
quences: (i) T1-weighted spin echo (SE) before and after
an intravenous gadolinium contrast injection; (ii) Short
Tau Inversion Recovery (STIR). The estimated scanning
time is 60 min. Images are acquired in two phases,
allowing patients to mobilize from the scanner for a
short time. MRI features of inflammation (ie: synovitis,
BMO or osteitis lesions) and damage (erosions, bone
formation, fat infiltration, sclerosis and/or ankylosis) will
be scored at peripheral joints, entheses and axial skel-
eton including sacroiliac joints and spine using a novel
scoring system.
US scanning of selected joints and entheses of lower
and upper limbs (see Table 3), is performed using a
multi-planar technique with symmetrical scanning by
sonographer blinded to the participant’s clinical charac-
teristics. Articular and entheseal sites will be assessed for
the presence of grey scale (GS) abnormalities and
power-Doppler (PD) signal. US pathological findings will
be identified according to the Outcome Measures in
Rheumatoid Arthritis Clinical Trials (OMERACT) defi-
nitions [45–47].
Patient-reported outcomes
The patients’ overall assessment of PsA activity will be
recorded at baseline and then at weeks 12, 24, 36 and
52, using the 100 mm horizontal VAS using the specific
Table 1 Eligibility criteria for randomization into the GOLMePsA
trial (Continued)
criteria 5) whilst receiving treatment and after the last dose of
protocol treatment as indicated in the relevant SmPC/IB.
27 Patients with a history of confirmed blood dyscrasia.
28 Patients with a history of mental illness that would interfere with
their ability to comply with the study protocol.
29 Patients with a history of drug and/or alcohol abuse that would
interfere with their ability to comply with the study protocol.
30 Patients with a history of any viral hepatitis within 1 year of screening.
31 Patients who have received or are expected to receive any live
virus or bacterial vaccinations or treatments that include live
organisms (e. g.: a therapeutic infectious agent such as the bacillus
of Calmette-Guerin (BCG) that is instilled into the bladder for the
treatment of cancer) within 3 months prior to the first administration
of the investigational medicinal product (IMP) and/or non
investigational medicinal products (NIMPs), during the trial, or
within 6 months after the last administration of the IMP and/
or NIMPs.
32 Patients who demonstrate hypersensitivity to the IMP and/or
NIMPs, or any of the excipients detailed in the relevant SmPC.
sDMARD synthetic disease modifying anti-rheumatic drug, TNFi Tumor necrosis
factor α inhibitor, WB-MRI whole-body magnetic resonance imaging
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Fig. 3 (See legend on next page.)
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wording proposed by Cauli et al. [48] for PsA. To calcu-
late the PsARC (at weeks 8, 12, 24, 36 and 52), the same
assessment will be also recorded on a Likaert scale ran-
ging from 1 to 5. All participants will fill in the Bath An-
kylosing Spondylitis Disease Activity Index (BASDAI)
[49] questionnaire at baseline and then at weeks 12, 24,
36 and 52. The outcomes relating to QoL and health sta-
tus are: the Health Assessment Questionnaire Disability
Index (HAQ-DI) [50] score; the Dermatology Life Qual-
ity Index (DLQI) [51] score; the Ankylosing Spondylitis
Quality Of Life (ASQOL) [52] score; the Short Form
(SF-36) [53] score. All these questionnaires will be col-
lected at baseline and then at 12, 24, 36 and 52 weeks.
Statistical analysis
Our null hypothesis (H0) is that the difference between
the two treatment arms in the PASDAS score at week 24
is equal to zero. Hence, the alternative hypothesis (H1)
is that the difference between the two treatment arms in
the PASDAS score at week 24 is not equal to zero. In
general, summary statistics (n = number of available
measurements; arithmetic mean; standard deviation; me-
dian; minimum and maximum) for quantitative variables
and absolute and relative frequency tables for qualitative
data will be presented. Analyses will be adjusted for the
randomisation stratification factor(s) and baseline values
of the outcome; 2-tailed tests will be performed and will
be considered statistically significant if p < 0.05.
Planned efficacy analyses
The primary endpoint will be assessed on an intention-
to-treat (ITT) basis. Analysis of covariance by multiple
linear regression will be used to compare PASDAS
between the two treatment groups at week 24. Binary
secondary endpoints will be analysed using multiple bin-
ary logistic regression. Continuous interval outcomes
will be analysed using multiple linear regression. Se-
verely skewed or ordinal outcomes will be analysed using
quantile regression. Planned subgroup analyses will
investigate differences in treatment response according
to oligo/polyarthritis status, immunological status, dis-
ease duration at baseline. A per protocol analysis will
also be performed.
Safety analyses
The frequency of all Serious Adverse Events (SAEs) dur-
ing the study period in patients who received at least 1
dose of study treatment will be presented for each treat-
ment group separately. The data will be displayed as
number of subjects experiencing the SAEs, percentage
(See figure on previous page.)
Fig. 3 Summary schedule of study assessments. 1, 2: Urinalysis and Pregnancy test can be repeated in other visits as clinically indicated. 3: If subjects do
not have a chest x-ray or hands/ft x-ray performed within 3 months of screening, an x-ray should be performed after it is certain the subject meets the
inclusion/exclusion criteria in order to minimize exposure to ionising radiation. 4, 5: Whole-body magnetic resonance imaging (WB-MRI) and ultrasound
(US) scans should be performed within 10 days before or after the scheduled visit attendance. Baseline assessment can take place 10 days before, but
not after, the scheduled visit attendance. 6, 7: No imaging (WB-MRI and/or US) to be performed if withdrawal visit occurs after week 36 or if within
6 weeks of last imaging. 8. Investigational Medicinal Product (IMP) administration should be every 4 weeks. In the case of a missed dose of IMP, the IMP
can be administered up to 2 weeks after the scheduled visit. If a dose of IMP is delayed for more than 2 weeks, the IMP should not be administered until
the next scheduled visit. Exposure to IMP should be captured in the medication workbook. * Study week X: withdrawal or early discontinuation. Subjects
who discontinue prematurely during Period 1 should return for the same assessments associated with Week 24 visit
Table 2 Description of the two treatment arms planned for the GOLMePsA trial
Treatment arm Treatment description
1 Golimumab
(IMP)
Monthly subcutaneous dose of 50 mg to be administered at the study site on baseline, week 4, 8, 12, 16, 20
and 24.
Subjects of ≥100 kg in weight will be given golimumab 100 mg monthly.
Methotrexate
(NIMP)
Starting oral dose of 15 mg weekly at baseline.
If tolerated, all participants will increase the weekly dose to 20 mg and 25 mg at weeks 2 and 4, respectively.
The drug will be kept at 25 mg, or the highest tolerated oral weekly dose, until the end of the study.
Subjects intolerant to oral formulation will switch to the subcutaneous one.
Methylprednisolone
(NIMP)
Single intra-muscular injection of 120 mg at baseline (or equivalent amount intra-articularly in case of
oligoarticular presentation, defined by the presence of ≤4 swollen joints).
Folic acid
(NIMP)
Daily oral dose of 5 mg, 6 days per week (except the day of methotrexate), until the end of the study.
2 Placebo Monthly subcutaneous administration at the study site on baseline, week 4, 8, 12, 16, 20 and 24.
Methotrexate As described for treatment arm 1
Methylprednisolone As described for treatment arm 1
Folic acid As described for treatment arm 1
Abbreviations: IMP Investigational medicinal product, NIMP Non-investigational medicinal product
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of subjects, and number of SAEs. Data will also be cor-
rected for exposure by 100 patient-years.
Handling of dropouts and missing data
For patients who withdraw early, data from the with-
drawal visit will be imputed for subsequent visits for
continuous outcomes, and non-response will be imputed
for binary outcomes. For all other instances of missing
data, multiple imputation will be used. A number of sen-
sitivity analyses testing robustness of conclusions under
different missing data mechanisms will be conducted.
Determination of sample size
Using in-house unpublished data, we estimated the
minimum clinically important difference to be 0.7 units
on the PASDAS; this is similar to a published value for
smallest detectable difference of 0.8 units [34]. We will
aim to detect a difference of at least 1 unit between the
treatment arms in this study. The standard deviation of
PASDAS in the Tight Control of Psoriatic Arthritis
(TICOPA) [54] MTX rapid escalation arm at 24 weeks
(restricted to patients who remained on methotrexate
throughout) was 1.57. Assuming δ = 1, σ = 1.57, at
alpha = 0.05 and 1-Beta = 0.8 this would require 78
patients; accounting for 10% drop-out we will aim to
recruit a total of 88 (44 per group).
Discussion
PsA is a costly disease both for the individual and the
society. Current treatment guidelines and treat-to-target
strategies are based on a step-up approach with
sDMARDs being the main staple of treatment, despite
limited data supporting their efficacy. The GOLMePsA
study aims to test the hypothesis that rapid control of
disease activity by aggressive abrogation of inflammation
with bDMARDs (GOL) in early diagnosed PsA will lead
to better outcomes at 24 weeks when compared to
sDMARD. Observing both arms up to 52 weeks will
allow us to investigate whether the anticipated benefit of
Table 3 Body areas undergoing magnetic resonance imaging (MRI) and ultrasound (US) evaluation
Articular Site Number of joints MRI US
Spine 42 X
Sacro-Iliac joints (SIJ) 2 X
Acromion-clavicular joints 2 X
Wrists 2 X X
Metacarpo-phalangeal joints (from 1 to 5) 10 X X
Proximal interphalangeal joints of the hands (from 1 to 5) 10 X X
Distal interphalangeal joints of the hands (2–5) 8 X
Hips 2 X
Knees 2 X X
Ankles 2 X X
Mid/Hind foot 2 X
Metatarso-phalangeal joints (from 1 to 5) 10 X X
Entheseal Site Number of areas
Lateral humeral epicondyle 2 X
Quadriceps insertion onto patella 2 X
Medial Femoral Condyle 2 X
Proximal patellar ligament insertion 2 X
Distal patellar ligament insertion 2 X
Achilles’ tendon distal insertion 2 X X
Plantar fascia proximal insertion 2 X X
Table 4 Eligibility criteria to gadolinium contrast-enhanced
magnetic resonance imaging at the Leeds Musculoskeletal
Biomedical Research Unit
Absence of previous reactions to gadolinium contrast
Absence of concomitant allergies to multiple drugs
Absence of severe allergies to drugs or food
Absence of a pacemaker
Absence of metallic implants (e. g.: cardiac valves, joint prostheses,
stents, cochlear implants)
Absence of metallic fragments in the eyes
Absence of unstable bronchial asthma
All criteria must be satisfied to fulfil eligibility
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early use of bDMARDs leads to sustained response while
on MTX monotherapy and better disease control at the
end of the observational period. In addition, rapid
optimization of disease management is expected to lead
to significant improvements in QoL of affected individ-
uals. A recent post-hoc analysis of the PRESTA trial pro-
vided some evidence on the superior efficacy of early
bDMARD use in PsA by showing that subjects treated
within 2 years of clinical onset had greater improve-
ments in disease activity outcomes and PROs [55] than
those with a longer disease duration. Data from an ob-
servational Swedish cohort [15] have highlighted the link
between shorter symptom duration at presentation and
a favourable outcome at 5 year follow-up. The GOL-
MePsA study was conceived in parallel to the running of
the TICOPA trial in our institution and before any re-
sults from the latter were available. Recent evidence
published since from the TICOPA trial [54] supports the
notion that early and intensive treatment ameliorates
disease activity effectively. These findings support our
initial hypothesis that shortening the time from symp-
tom onset to diagnosis, coupled with an aggressive
therapeutic approach, should provide a window of op-
portunity for optimal management of PsA. The GOL-
MePsA trial will compare two different treatment
combination strategies for PsA (single corticosteroid in-
jection plus MTX plus bDMARD versus single cortico-
steroid injection plus MTX). This translates into both
treatment arms receiving active medication (MTX and
corticosteroids). These interventions will allows us to
gather more data concerning the efficacy of early inten-
sive treatment strategies in PsA and to characterize the
role of bDMARD therapy early in the course of the dis-
ease. This study design will also provide important in-
sights concerning the efficacy and safety of a “step
down” strategy with bDMARDs followed by MTX main-
tenance in contrast to a more cautionary “step up” ap-
proach (bDMARDs following sDMARDs failure or
intolerance). The effect of adding sDMARDs to MTX in
early PsA patients stepping down from bDMARDs will
also be explored.
Further, the GOLMePsA trial is collecting data from
several clinical manifestations of PsA (articular and cuta-
neous involvement, entheses, dactylitis and nail disease).
The choice of PASDAS as primary outcome will contrib-
ute to explore issues of multidimensionality in a hetero-
geneous condition like PsA. From the regulatory/ethic
point of view, however, PsARC was chosen to manage
efficacy decisions at weeks 8–12 as a reflection of
current treatment guidelines in the UK.
Further, more evidence will become available on the
efficacy of high-dose MTX as initial agent in the treat-
ment of the early phases of PsA. Previous studies explor-
ing this issue have reported promising results [16, 56],
although they could have potentially underestimated the
presence of a dose effect. One of the main findings from
the TICOPA trial was the apparently higher number of
side effects reported on the tight control arm. The main
difference between the GOLMePsA study and the
TICOPA trial is the earlier exposure to bDMARDs as
part of an aggressive combination strategy also incorpor-
ating methotrexate and steroids. This could lead to
higher toxicity than the conventional treatment arm,
although our experience, with nearly 25% of the GOL-
MePsA subjects recruited, has not raised such concerns
so far.
Finally, GOLMePsA uses an imaging package compris-
ing WB-MRI and US to assess the overall burden of
inflammation in early PsA. This will allow for the
characterization of bulk of subclinical disease as a pos-
sible biomarker of treatment response and prognosis at
24 and 36 weeks.
Trial status
The first patient was enrolled in GOLMePsA in Novem-
ber 2015 with recruitment planned to end in April 2018.
There are an estimated 4–6 eligible subject per month
seen in our Early Arthritis and Spondyloarthritis clinics,
yielding a possible 48 eligible patients per year. Since
opening, the trial has undergone minor protocol amend-
ments (current version 4.0). All these are reflected in the
present paper.
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